{"id":"W4229062082","doi":"10.1016/j.annonc.2022.03.185","title":"166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Oncology; Internal medicine; Tolerability; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006117627,0.0006327445,0.001832319,0.0003680126,0.000702266,0.00001613743,0.0004525675,0.0001239655,0.001440775],"category_scores_gemma":[0.0005455798,0.0005860563,0.0003420711,0.0007022669,0.0003670588,0.0002991007,0.00033836,0.0004610126,0.00001166157],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001127165,"about_ca_system_score_gemma":0.002454305,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007939098,"about_ca_topic_score_gemma":0.006312107,"domain_scores_codex":[0.9952244,0.0004985984,0.001402639,0.001189091,0.0007207679,0.0009645185],"domain_scores_gemma":[0.9954918,0.001363114,0.001010676,0.0009317718,0.0008192919,0.000383349],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2166553,0.02613317,0.000378501,0.0001072078,0.003922378,0.00100496,0.01135746,0.004961371,0.001776671,0.00009273843,0.001703338,0.7319069],"study_design_scores_gemma":[0.4282435,0.2842943,0.003568283,0.0004542722,0.002640231,0.001212746,0.02481564,0.002503694,0.0248259,0.01062793,0.2151216,0.001691822],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9527605,0.002110238,0.000747774,0.01657541,0.000811781,0.006018649,0.02026165,0.0001376064,0.0005764105],"genre_scores_gemma":[0.9885737,0.0004507674,0.002464047,0.00169361,0.0004491944,0.00407493,0.0009400461,0.0001274704,0.001226198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7302151,"threshold_uncertainty_score":0.9996591,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1129353961526078,"score_gpt":0.4609971678987615,"score_spread":0.3480617717461537,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}